Skip to Primary Navigation Skip to Site Navigation Skip to Main Content All 3M.com Site Map

3M licenses Dry Powder Inhaler technology from Cambridge Consultants


ST. PAUL, Minn. – December 10, 2008 – 3M Drug Delivery Systems announces the signing of an exclusive technology license and purchase agreement with Cambridge Consultants for its ConixTM Dry Powder Inhaler (DPI) technology platform. The Conix DPI technology, also called reverse-flow cyclone technology, adds to 3M's extensive inhalation technology platform.

"This new technology platform enhances 3M's capability to provide partner pharmaceutical and biotechnology companies with innovative drug delivery solutions," said James Vaughan, division vice president, 3M Drug Delivery Systems Division. "We believe the Conix technology will add to the breadth of our unique inhalation technology portfolio and enables us to offer new and exciting drug delivery alternatives."

The Conix technology platform includes a variety of inhaler types, ranging from a single dose device suitable for applications such as immunizations, to a multi-unit dose suitable for routine therapies, such as, asthma and COPD.

3M Drug Delivery Systems has more than 50 years of experience and proven success in inhalation technologies. 3M offers a full range of inhalation technology platforms from pressurized metered-dose inhalers (pMDI) to components - including cans, valves and dose counters.

About 3M Drug Delivery Systems
3M Drug Delivery Systems partners with pharmaceutical and biotech companies to develop pharmaceuticals using 3M's inhalation or transdermal drug delivery technology. 3M offers a full range of feasibility, development and manufacturing capabilities combined with regulatory guidance to help bring products to market. In-house resources, including toxicology, regulatory expertise, quality assurance, operations, and marketed product support, are available for each step of the development and commercialization process. This depth of resources is one reason why more than 50 percent of all metered-dose inhalers worldwide and 80 percent of all transdermal systems in the United States utilize 3M drug delivery technology. For more information, please visit www.3M.com/dds or call 1-800-643-8086.

Contact:
Stephanie Sanderson
(651) 733-8588
sjsanderson@mmm.com

Back